Related by context. All words. (Click for frequent words.) 72 experienced hypomagnesemia 69 acneform rash 69 receiving INTRON 69 oral allopurinol 69 plus dexamethasone 68 peripheral sensory neuropathy 67 dermatologic toxicities 67 Hypomagnesemia occurred 67 mcg kg REBETOL 67 lopinavir r arm 67 highly emetogenic 66 plus gemcitabine 66 DOXIL 66 Peg IFN 66 events AEs 66 pyrexia mucositis sepsis febrile 65 Acneform rash occurred 65 neutropenia dehydration dyspnea 65 febrile neutropenia 64 discontinuations due 64 ACTEMRA TM 64 dacarbazine 64 Folfox 64 neutropaenia 64 KRAS mutations occur 64 chlorambucil 64 FluCAM arm 64 Flu Cy 64 FOLFIRI 64 4mg/kg 64 Infusion Reactions Severe 64 metastatic GIST 63 laboratory abnormalities 63 hypomagnesemia 63 8mg/kg 63 hematologic toxicity 63 FOLFOX 63 superficial edema 63 receiving PEGINTRON 63 lymphopenia 63 generalized edema 63 FOLFOX4 63 alfa 2a 63 treatment emergent adverse 63 TEAEs 63 myalgia arthralgia 62 ribavirin RBV 62 mg TID 62 FOLFIRI alone 62 events thrombocytopenia neutropenia 62 prednisone prednisolone 62 alpha interferons 62 mcg BID 62 refractory NSCLC 62 hypokalemia 62 severe hypersensitivity reactions 62 fluorouracil leucovorin 62 mg m² 62 TORISEL 62 hematologic adverse 62 nasopharyngitis 62 #mg BID [003] 62 interferon alfa 2a 62 CIMZIA ™ 62 certolizumab 62 severe neutropenia 61 oral levofloxacin 61 PREZISTA r arm 61 5-FU/LV 61 infliximab monotherapy 61 cisplatin gemcitabine 61 Discontinuations due 61 pegylated interferon alfa 2a 61 docetaxel chemotherapy 61 cisplatin vinorelbine 61 Fludara 61 VELCADE melphalan 61 hypophosphatemia 61 FOLFOX4 alone 61 mucositis 61 relapsed MM 61 headache nasopharyngitis 61 μg dose 61 achieved ACR# 61 thrombocytopenia anemia 61 mg BID 61 placebo dexamethasone 61 incidence ≥ 61 unresectable HCC 61 microbiological eradication 61 PREZISTA ritonavir 61 FOLFOX6 61 oxycodone CR 61 VFEND 61 adjunctive placebo 61 receiving VICTRELIS 61 carboplatin paclitaxel 60 ug dose 60 relapsed CLL 60 comparator arm 60 APTIVUS r 60 oral diclofenac 60 gemcitabine cisplatin 60 events SAEs 60 FluCAM 60 bendamustine 60 linaclotide treated 60 daunorubicin 60 HCV SPRINT 60 ALT flares 60 neutropenia thrombocytopenia 60 plus prednisone prednisolone 60 pyrexia 60 rizatriptan 60 beclomethasone dipropionate 60 salmeterol fluticasone 60 treatment naive genotype 60 leukopenia 60 melphalan prednisone 60 fluticasone salmeterol 60 receiving ISENTRESS 60 lamivudine refractory patients 60 HBeAg negative patients 60 CIMZIA TM certolizumab pegol 60 low dose cytarabine 60 pegylated interferon alpha 60 ribavirin therapy 60 leucopenia 60 IXEMPRA 60 estramustine 60 PROCTOCORT ® Suppository Hydrocortisone 60 stomatitis 60 posaconazole 60 receiving VELCADE 60 REYATAZ r arm 60 TAXUS p value 60 ceftazidime 60 PREZISTA r 59 voriconazole 59 tumor lysis syndrome 59 Elitek 59 amphotericin B 59 Q2W 59 receiving XGEVA 59 arterial thromboembolic events 59 CIMZIA TM 59 refractory gout 59 fatigue asthenia 59 thrombocytopenia 59 biologic DMARD 59 mcg QD 59 Peginterferon Alfa 2a 59 naïve HCV 59 interferon alfa 2b 59 PegIFN 59 limiting toxicity 59 dexamethasone Decadron 59 mg QD 59 mapatumumab 59 HBeAg seroconversion 59 ARCOXIA 59 RAPTIVA 59 PEGylated anti 59 adjunctive ABILIFY 59 neutropenia 59 pegylated liposomal doxorubicin 59 Adverse events 59 patients evaluable 59 TMC# r 59 adriamycin 59 partial remissions 59 MCyR 59 gastrointestinal perforation 59 evaluable subjects 59 gastrointestinal toxicities 59 nicardipine 59 PegIFN RBV 59 hepatic failure 59 thrombocytopenia neutropenia 59 Hypersensitivity reactions 59 recurrent VTE 59 FOLPI 59 Neutropenia 59 nab paclitaxel 59 plus methotrexate 59 stage IIIb IV 59 neutropenic fever 59 Lactic acidosis 59 Pegasys ® 59 doripenem 59 ara C 59 Febrile neutropenia 59 CR CRu 59 mg qd 59 non splenectomized 59 mcg albinterferon alfa 2b 58 tipranavir r 58 azathioprine 58 Serious adverse reactions 58 cyclophosphamide methotrexate 58 hematological adverse 58 peripheral edema 58 q8h 58 ARCALYST ® 58 del 5q MDS 58 mg administered orally 58 lopinavir r 58 Dermatologic toxicities 58 systemic absorption 58 moderately emetogenic 58 Cream USP 1 58 Acetate Rectal Suppositories 58 tapentadol ER 58 vinorelbine 58 peginterferon alfa 58 mg/m2 IV 58 #mg/m# [001] 58 IIIa inhibitor 58 mcg kg 58 primary hypercholesterolemia 58 hypercalcemia 58 diarrhea vomiting nausea 58 % Confidence Interval 58 HBeAg positive patients 58 recurrent glioblastoma multiforme 58 Pharmacokinetics PK 58 Treatment emergent adverse 58 diarrhea nausea vomiting 58 plus ribavirin 58 doxorubicin cyclophosphamide 58 CR nPR 58 cSSSI 58 ATACAND 58 infusion reactions 58 TYSABRI treated 58 lenalidomide dexamethasone 58 CANCIDAS 58 q#h 58 neutropenia febrile neutropenia 58 interferon gamma 1b 58 mCi kg 58 dapagliflozin plus 58 ALT elevation 57 pooled comparator 57 PEGINTRON 57 Thrombocytopenia 57 reinfarction 57 QTc prolongation 57 hepatitis C genotype 57 hypersensitivity reactions 57 potentially hepatotoxic 57 treatment naïve genotype 57 lispro 57 BUPHENYL 57 plus prednisone 57 nadolol 57 Median PFS 57 iniparib BSI 57 plus COPEGUS 57 BARACLUDE ® 57 conjunctival hyperemia 57 plus GP IIb 57 BUPHENYL R sodium phenylbutyrate 57 interferon alfa 57 ertapenem 57 achieved CCyR 57 mg kg dose 57 severe exacerbations 57 piperacillin tazobactam 57 carboplatin 57 pruritis 57 mitomycin 57 fluorouracil 57 nonfatal MI 57 peg IFN 57 neutropenic sepsis 57 KRAS wild 57 TMP SMX 57 mg/# h 57 XELOX 57 thromboembolic events 57 REBETOL 57 HCV RESPOND 2 57 mg q#h 57 tolterodine ER 57 mg/m2 dose 57 nonhematologic adverse reactions 57 COPEGUS 57 log# IU mL 57 mg dosed twice 57 5FU 57 desvenlafaxine succinate 57 amprenavir 57 peginterferon alfa 2a 57 monotherapy 57 virologic breakthrough 57 CCyR 57 Taxotere R 57 dose limiting toxicities 57 mitoxantrone plus 57 locoregional recurrence 57 ALT elevations 57 benazepril 57 Engerix B 57 iobenguane 57 potent CYP#A# inhibitors 57 zonisamide SR 57 levofloxacin 56 Mg Uk 56 octreotide LAR 56 imipenem 56 receiving highly emetogenic 56 ritonavir boosted 56 #mg QD [002] 56 endometrial hyperplasia 56 pancytopenia 56 Tarceva TM 56 elevated ALT 56 μg doses 56 ritonavir boosted atazanavir 56 mg/m2/day 56 Renal impairment 56 DLTs 56 Treatment discontinuations due 56 angioneurotic edema 56 remission induction 56 R# #mg BID 56 pomalidomide 56 oral rivaroxaban 56 morphometric vertebral fractures 56 achieved PASI 56 clodronate 56 stage IIIB 56 PEG IFN 56 log# copies mL 56 hepatotoxicity 56 chemotherapy induced neutropenia 56 mg RDEA# 56 amoxicillin clavulanate 56 Hypotension 56 myopathy rhabdomyolysis 56 events TEAEs 56 EXJADE 56 CHOP chemotherapy 56 x ULN 56 #mg BID [001] 56 renal insufficiency 56 GEMZAR 56 Capecitabine 56 dose cohort 56 MACCE 56 #mg/m# [002] 56 % CI #.#-#.# [003] 56 mg Proellex 56 oral antidiabetic medication 56 ascending doses 56 nadroparin 56 pericardial effusion 56 3mg/kg 56 AEs 56 pruritus 56 HBeAg positive 56 tenofovir emtricitabine 56 peginterferon alfa 2b 56 Known hypersensitivity 56 LPV r 56 nonfatal stroke 56 nausea dizziness vomiting 56 locoregional 56 somnolence dizziness 56 PEGASYS ® 56 pegylated interferon alfa 55 dose cytarabine 55 isoproterenol 55 moderate renal impairment 55 elotuzumab 55 TAXOTERE R 55 LANTUS R 55 aminotransferase elevations greater 55 RLAI 55 Monotherapy 55 #/#.# mcg 55 flutamide 55 saline placebo 55 cSSSIs 55 events MACE 55 prednisone prednisolone plus 55 log# reduction 55 antiarrhythmic drug 55 sensory neuropathy 55 telaprevir dosed 55 docetaxel prednisone 55 Pegasys plus Copegus 55 overt nephropathy 55 VIIBRYD 55 q#d 55 haematologic 55 Erythropoietic therapies may 55 mCRC patients 55 p = NS 55 tirofiban 55 budesonide pMDI 55 squamous histology 55 PEG Interferon alfa 55 anaphylactoid reactions 55 Telintra 55 severe hypoglycemic 55 Exacerbations 55 external genital lesions 55 #mg #mg #mg [003] 55 Discontinuations 55 placebo PBO 55 KRAS mutant tumors 55 heparin induced thrombocytopenia 55 caspofungin 55 insulin glulisine 55 Hepatotoxicity 55 definite stent thrombosis 55 idraparinux 55 paclitaxel carboplatin 55 SVR# 55 hallucinations dyskinesia 55 malignancy HCM 55 pemetrexed 55 thrombotic events 55 headache abdominal pain 55 azathioprine monotherapy 55 â ‰ ¥ 55 inhaled fluticasone 55 QD dosing 55 #.#/#.# mmHg [001] 55 mg BID dose 55 composite endpoint 55 hemorrhagic cystitis 55 PRADAXA #mg 55 prucalopride 55 evaluable 55 unfractionated heparin UFH 55 INVEGA ® 55 NovoLog ® Mix 55 mg/m2 55 mucositis stomatitis 55 OADs 55 VAPRISOL 55 HBeAg negative 55 fluoropyrimidine 55 progressive PsA 55 anemia leukopenia 55 Partial Responses 55 mycophenolate mofetil 55 recurrent venous thromboembolism 55 uncontrolled seizures 55 pegIFN 55 pegylated interferon alfa 2b 55 unstable angina pectoris 55 hepatic dysfunction 55 cytopenias 55 alkylating agent 55 decitabine 55 NNT = 55 telaprevir dosing 55 tolvaptan 55 didanosine associated 55 Taxotere ® 55 % CI #.#-#.# [007] 55 ALVESCO 55 Stent thrombosis 54 severe renal impairment 54 abacavir lamivudine 54 delayed CINV 54 biochemical relapse 54 tiotropium bromide 54 splenectomized 54 #mg q8h 54 chronic HCV genotype 54 mg/# hr 54 non hematological toxicities 54 mg doses 54 Entereg R 54 discontinuations 54 acromegalic patients 54 venous thromboembolic events 54 constipation nausea 54 timolol 54 ocular adverse 54 #mg doses [002] 54 #.#g/day 54 neutropenia anemia 54 tobramycin inhalation solution 54 iodixanol 54 extrapyramidal symptoms 54 Auxilium anticipates 54 baseline HbA1c 54 NPH insulin 54 median PFS 54 REMICADE ® 54 metastatic RCC 54 LEXIVA r 54 salmeterol HFA MDI 54 nucleoside naive 54 vitamin B# folic acid 54 Hematologic 54 REBETOL therapy 54 binary restenosis 54 ABC/3TC 54 concomitant AEDs 54 mg eq 54 arterial thromboembolic 54 Acute Coronary Syndromes ACS 54 RGT arm 54 alpha 2a 54 doxorubicin docetaxel 54 ipsilateral breast 54 HBeAg 54 recurrent DVT 54 symptomatic VTE 54 nasopharyngitis headache 54 myelosuppression 54 ARIXTRA 54 mucosal inflammation 54 temsirolimus 54 free survival PFS 54 fulminant hepatitis 54 nodular partial response 54 pegylated interferon 54 neck receiving ERBITUX 54 nephrotoxicity 54 dose dexamethasone 54 chemoradiation therapy 54 FOLPI regimen 54 MADRS score 54 transaminase elevations 54 palonosetron 54 #.#mg/kg [002] 54 alfa 2b 54 Chronic hepatitis C 54 LEXIVA 54 capecitabine 54 pheochromocytoma 54 ipsilateral stroke 54 hypoglycemic events 54 ethambutol 54 hour bronchodilation 54 HMG CoA reductase inhibitors 54 ischemia driven 54 VT VF 54 #mg/day [001] 54 idarubicin 54 dihydrochloride 54 hepatic metastases 54 transaminase 54 paclitaxel chemotherapy 54 IFN α 54 mg ustekinumab 54 Median progression 54 anemia neutropenia 54 Serious ocular 54 COPD exacerbation 54 5 fluorouracil 54 rFVIIa 54 EURIDIS 54 liver decompensation 54 dosing cohorts 54 IU ml 54 symptomatic BPH 54 mRCC 54 venlafaxine ER 54 virological response 54 hours postdose 54 MIC# [001] 54 6 mercaptopurine 54 pamidronate 54 mcg mL 54 HCV genotype 1 54 pegylated alpha interferon 54 adalimumab 53 intracranial hemorrhage ICH 53 SCH # 53 #mg dosing group 53 dose cohorts 53 spinal cord compression 53 daily Infergen 53 mg m 53 rFSH 53 mg dose 53 BENICAR HCT 53 inhaled budesonide 53 administered subcutaneously 53 null responder 53 dexamethasone 53 hyperphenylalaninemia HPA due 53 oral prednisolone 53 confidence interval #.#-#.# 53 dosage regimens 53 ACR# response 53 lymphocytosis 53 panitumumab Vectibix 53 HAM D# scores 53 ‰ ¥ 53 metformin accumulation 53 INTEGRILIN ® 53 metformin monotherapy 53 evaluable patients 53 Torsades de Pointes 53 aspartate aminotransferase AST 53 ancrod 53 completely resected 53 Operative mortality 53 hemorrhagic complications 53 azacitidine 53 TDF FTC 53 atazanavir ritonavir 53 Anturol 53 unknown etiology 53 plus glycoprotein IIb 53 SAEs 53 corticosteroid dose 53 mg/m2 administered 53 dosed orally 53 PASI scores 53 % CI #.#-#.# [005] 53 non valvular atrial 53 achieved statistical significance 53 lumbar spine bone 53 Apidra ® 53 angioedema 53 mitoxantrone 53 underwent surgical resection 53 COZAAR 53 mg q8h 53 microgram kg 53 IV bolus 53 mg simvastatin 53 statin monotherapy 53 alanine aminotransferase 53 gout flare 53 NNRTI resistance 53 EFFEXOR XR 53 cardiac toxicity 53 postoperative ileus POI 53 ischemic cardiovascular 53 plus MTX 53 renal toxicity 53 cholecystitis 53 NMIBC 53 dasatinib 53 pT3 53 thrombophlebitis 53 Psoriasis Area 53 Hepatic Impairment 53 HCV genotype 53 nonfatal myocardial infarction 53 intravesical therapy 53 hematological toxicity 53 achieved mucosal healing 53 distant metastasis 53 mg tid 53 palmar plantar 53 thromboembolic 53 albinterferon alfa 2b 53 dalteparin 53 low dose dexamethasone 53 mcg doses 53 intravenous bisphosphonates 53 Anaphylactic reactions 53 BANZEL 53 diarrhea headache nausea 53 XIENCE V demonstrated 53 paliperidone ER 53 QTcF 53 arthralgia 53 active comparator 53 perioperatively 53 null responder HCV 53 injected subcutaneously 53 paresthesias 53 hematologic abnormalities 53 dose dose escalation 53 Adverse reactions 53 CRp 53 mg d 53 REVLIMID lenalidomide 52 budesonide formoterol 52 dysuria 52 Ceplene/IL-2 52 advanced adenoma 52 Traficet EN 52 virological failure 52 hypocalcemia 52 dermatologic reactions 52 Free Survival PFS 52 bone marrow suppression 52 nonmetastatic 52 Severe hypersensitivity reactions 52 BEACOPP 52 tacrolimus ointment 52 darunavir ritonavir 52 solifenacin 52 anemia hemoglobin 52 pulmonary exacerbations 52 peginterferon alpha 2a 52 Omacetaxine mepesuccinate 52 prolonged QT interval 52 symptomatic pulmonary embolism 52 bortezomib 52 hyperbilirubinemia 52 insomnia somnolence 52 pegaptanib 52 #mg dose [002] 52 radiotherapy RT 52 hematological toxicities 52 mg p = 52 HeFH 52 ARIKACE 52 ug kg 52 placebo p = 52 REYATAZ r 52 fluticasone 52 XIENCE V PROMUS Stent 52 relapsed MCL 52 neurologic progression 52 RISPERDAL ® 52 #.#mg/dL 52 oral olanzapine 52 terfenadine 52 gemcitabine 52 HGPIN 52 hyperkalemia 52 syncope fainting 52 remission CR 52 Contrave# 52 aspartate aminotransferase 52 CIPN 52 thromboembolic complications 52 underwent resection 52 EBRT 52 oxymorphone ER 52 clotrimazole 52 gadobutrol 52 paclitaxel eluting stents 52 inflammatory lesions 52 bolus dose 52 intravitreal injections 52 ALT normalization 52 simvastatin ezetimibe 52 #mg BID [002] 52 tiotropium 52 IOP lowering 52 myocardial infarction stroke 52 mcg dose 52 thrombotic thrombocytopenic purpura TTP 52 mg kg REMICADE 52 cGy 52 zolmitriptan 52 maximally tolerated dose 52 goserelin 52 darbepoetin alfa 52 -#.# log# copies mL 52 fumarate 52 mcg linaclotide 52 Peripheral edema 52 placebo controlled clinical trials 52 q# 52 acitretin 52 QT prolongation 52 octagam ® 52 balsalazide 52 recurrent ischemia 52 DAS# CRP 52 primidone 52 generalized tonic clonic seizures 52 Pharmacokinetic parameters 52 n = 52 TAXOTERE ® 52 elevated transaminases 52 periprocedural 52 progression TTP 52 ONGLYZA 52 abciximab 52 neutropenic patients 52 placebo intravenously 52 ULORIC 52 intraocular inflammation 52 containing abacavir 52 AVANDIA 52 papillary renal cell carcinoma 52 prior chemotherapy regimens 52 efavirenz EFV 52 Severe allergic reactions 52 pyrazinamide 52 mild renal impairment 52 melphalan 52 insulin detemir 52 headache nausea diarrhea 52 mg iv peramivir 52 antiepileptic 52 parecoxib 52 pimecrolimus cream 52 AML MDS 52 Median survival 52 adefovir treated 52 HF hospitalization 52 pyrimidine nucleoside analog 52 CrCl 52 serious Interstitial Lung 52 sunitinib 52 concurrent chemoradiation 52 DETROL LA 52 gemifloxacin 52 ceftriaxone 52 Discontinuation 52 oxycodone IR 51 postmenopausal osteoporotic women 51 lamivudine 51 Solid Tumors criteria 51 micrograms mL 51 Neuroleptic Malignant Syndrome NMS 51 hematologic toxicities 51 TNF antagonist 51 lung metastases 51 sotalol 51 achieved sustained virological 51 mucocutaneous reactions 51 nephrotoxic 51 fatal anaphylactic 51 #mg dose [003] 51 dosing cohort 51 Oral mucositis 51 corticosteroid therapy 51 tobramycin 51 Pruvel 51 tamsulosin 51 nondiabetic patients 51 CTA# Injection 51 granisetron 51 Secondary endpoints include 51 ascending dose 51 pCR 51 EDSS scores 51 IFN alfa 51 mEq 51 mg orally 51 mg kg 51 5mg/kg 51 APTIVUS ritonavir 51 μg mL 51 linezolid 51 CI #.#-#.# [002] 51 serum phosphate 51 locoregional disease 51 antiandrogen 51 corrected QT interval 51 etoposide 51 urate lowering 51 antiretroviral naïve 51 rapid virologic response 51 neoadjuvant 51 febuxostat 51 toxicities 51 p ≤ 51 lamivudine monotherapy 51 Hypocalcemia 51 radiation dermatitis 51 CIMZIA R 51 lumbar spine BMD 51 venlafaxine XR 51 TNF blocker therapy 51 seroconverted 51 virologic failure 51 SGPT 51 ischemic complications 51 Thrombotic events 51 Skin rashes 51 coinfected patients 51 GSK# [001] 51 docetaxel 51 CLL SLL 51 cerebrovascular events 51 peginterferon 51 symptomatic NOH 51 histologically confirmed 51 titrated glipizide 51 biphasic insulin aspart 51 androgen suppression 51 liver histology 51 randomized #:# 51 T2DM 51 advanced adenomas 51 ropivacaine 51 lenalidomide 51 LIALDA 51 tolerability 51 splenectomized patients 51 μg kg 51 inhalations twice 51 colorectal adenoma 51 valopicitabine 51 plasma uric acid 51 irbesartan 51 subcutaneous injections 51 kBq kg 51 intramuscularly 51 bortezomib refractory 51 norethindrone 51 confidence interval CI 51 stroke myocardial infarction 51 TURBT 51 serum HCV RNA 51 ritonavir boosted lopinavir 51 chemoradiotherapy 51 Secondary endpoints included 51 adefovir 51 chronic idiopathic thrombocytopenic purpura 51 mL/min/#.# m 2 51 achieved sustained virologic 51 CC genotype 51 anaphylactic reactions bronchospasm 51 salmeterol fluticasone propionate 51 mild renal insufficiency 51 warfarin erythromycin 51 erythema redness 51 seropositivity 51 SCIg 51 thrombocytopenic 51 lomitapide 51 prolonged cytopenias 51 adverse cytogenetics 51 pharmacokinetics PK 51 β blockers 51 azacytidine 51 rheumatoid arthritis HUMIRA 51 mesalamine granules 51 torsemide ER 51 concomitant medications 50 unfractionated heparin 50 lactic acidosis 50 Helicobacter pylori eradication 50 related hematological toxicity 50 bosentan 50 #-#,# mg 50 syncopal 50 lacosamide 50 pmol liter 50 Serious Adverse Events 50 certolizumab pegol 50 Fibrillex TM 50 noninferior 50 mg Lucentis 50 glucuronide 50 ventricular fibrillation VF 50 TMC# [001] 50 FLT3 ITD 50 statistically significant p = 50 continuous intravenous infusion 50 APIDRA R 50 STELARA 50 fosamprenavir 50 mU liter 50 peginterferon alfa 2a #KD 50 mg/# hours 50 paroxysmal AF 50 TRISENOX 50 cerebrovascular accidents 50 fluticasone furoate 50 confirmed thrombotic cardiovascular 50 bleeding ulceration 50 intra articular injection 50 transurethral resection 50 symptomatic hyponatremia 50 subcutaneously administered 50 intravenous REOLYSIN 50 electrolyte abnormalities 50 preoperative chemotherapy 50 EMEND 50 cutaneous lupus 50 unfavorable cytogenetics 50 lopinavir ritonavir 50 darunavir r 50 μmol L 50 sUA 50 mg kg ip 50 intravenous bolus 50 Aggrastat ® tirofiban hydrochloride 50 Hematologic toxicity 50 RISPERDAL 50 INTEGRILIN 50 AUC0 50 mitomycin C 50 prospectively stratified 50 chronic urticaria 50 Moli# 50 P = .# 50 antiretroviral naive 50 dysmenorrhoea 50 injected intramuscularly 50 serum urate 50 torsade de pointes 50 mEq L 50 EUFLEXXA R